Ruby Khoury, MD

Long-term Follow-up After Mixed Donor Myeloid Chimerism at 1 Year Post Transplantation for Sickle Cell Disease. Guilcher, GMT; Dalal, S; Suresh, T; Yelamali, AR; Arora, J; Aljayyousi, H; Bhatia, M; Haight, AE; Khandelwal, P; Khoury, R; Shah, NC; Stenger, EO; Yelamanchili, N; Shenoy, S. Transplantation and Cellular Therapy. 2026; 32(6):709.e1-709.e10.

Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates. Galletta, TJ; Rubinstein, JD; Dandoy, CE; Khoury, R; Faulhaber, A; Phillips, CL; Krupski, C. Pediatric Blood and Cancer. 2026; e70406.

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT. Davies, SM; Blyth, E; Bollard, CM; Craddock, J; Dahi, PB; Gottlieb, D; Grimley, MB; Keller, MD; Khoury, R; Olson, AL; Spivey, SM; Vasileiou, S; Prockop, SE; Heslop, HE. Transplantation and Cellular Therapy. 2026.

LONG-TERM CRYOPRESERVATION PRESERVES THE BIOLOGICAL AND MECHANOBIOLOGICAL ACTIVITY OF THIRD-PARTY VIRUS-SPECIFIC T CELLS. Ikegami, S; Pandey, V; Wang, X; Sridharan, A; Mccormack-Spivey, S; Lutzko, CM; Cancelas, JA; Heyenbruch, D; Leemhuis, T; Alquist, CR; Khoury, R; Rubinstein, JD; Davies, S; Grimley, M. Cytotherapy. 2026; 28(5):102608.

2’-Fucosyllactose (Human Milk Oligosaccharide) Reduces Dysbiosis and Acute GI GVHD in Children and Young Adults Following HSCT: A Prospective, Single-Center Phase II Study. Ramos, KN; Langenberg, L; Lake, KE; Hoerth, C; Luebbering, N; Haslam, D; Newburg, D; Morrow, AL; Ollberding, NJ; Teusink, A; Watanabe-Chailland, M; Romick-Rosendale, L; Davies, SM; Khandelwal, P. Transplantation and Cellular Therapy. 2026; 32(2):s570.

Duration of Cryopreservation of Third-Party Viral Specific T-Cells (TP-VSTs) Does Not Influence Clinical Efficacy. Mccormack-Spivey, S; Wilhelm, J; Ikegami, S; Rubinstein, JD; Hudda, Z; Khoury, R; Davies, SM; Grimley, MS. Transplantation and Cellular Therapy. 2026; 32(2):s131.

Biomarker Elevations Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome after CD19-Directed CAR-T Therapy in Children and Young Adults with Acute B-Lymphoblastic Leukemia. Galletta, TJ; Rubinstein, JD; Krupski, C; Dandoy, CE; Khoury, R; Faulhaber, A; Davies, SM; Phillips, CL. Transplantation and Cellular Therapy. 2026; 32(2):s177.

Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction. Rubinstein, JD; Pham, G; Sridharan, A; Khoury, R; Wang, YM; Hudda, Z; Wilhelm, J; Lichtenstein, DA; Heyenbruch, D; Cancelas, JA; Davies, SM; Lutzko, C; Grimley, MS. Blood advances. 2025; 9(24):6305-6313.

Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation. Ibrahimova, A; Khoury, R; Jodele, S; Grimley, M; Davies, SM; Khandelwal, P. Bone Marrow Transplantation. 2025; 60(8):1102-1107.

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. Marsh, R; Khoury, R; Mizuno, K; Hosawi, A; Cottrell, C; Nguyen, E; Landon, B; Chandra, S; Jordan, M; Kumar, A; Bleesing, J; Davies, S; Moore, C; Mehta, P. Journal of Human Immunity. 2025; 1(CIS2025).